Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab and Lenalidomide in R/R Mantle Cell Lymphoma
NCT05788289Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate. Started Mar 2023; status: terminated.
02
Drugs
tafasitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05788289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788289.